The presence of thrombocytosis is independent of biologic characteristics that help classify breast cancer to subgroups relevant for treatment such as ER/PR and Her-2 expression and thus has value beyond these characteristics. This evidence concerns the gene ERBB2 and thrombocytosis disease.